Introduction:
Dapagliflozin is a sodium glucose co transporter 2 inhibitor, which can be used as an important choice in the treatment of diabetes mellitus. It can be used as an assistant diet and exercise to improve blood glucose control in adults with type 2 diabetes.
CAS:461432-26-8
Molecular formula: C21H25ClO6
Molecular weight: 408.88
Structural type:
Pharmacological action:
Dapagliflozin works by inhibiting sodium glucose transporter 2 (SGLT2), a protein in the kidney that reabsorbs glucose into the blood. This allows excess glucose to be excluded from the body through the urine, thereby improving blood glucose control without increasing insulin secretion. The use of this drug requires normal renal function, and it is forbidden for patients with moderate to severe renal insufficiency. Combined use of metformin, pioglitazone, glimepiride and insulin can significantly reduce HbA1c and fasting blood glucose in patients with type 2 diabetes. The incidence of adverse reactions is similar to that of placebo. Low risk of hypoglycemia can reduce body weight.